Financial Performance - The company's operating revenue for the first half of 2022 was ¥12,706,434,721.05, representing a 1.15% increase compared to ¥12,561,786,991.15 in the same period last year[20]. - The net profit attributable to shareholders decreased by 3.24% to ¥169,486,663.20 from ¥175,169,586.50 year-on-year[20]. - Basic earnings per share decreased by 3.33% to ¥0.58 from ¥0.60 in the same period last year[20]. - The company reported a total profit for the first half of 2022 of ¥342,968,680.24, down 20.29% from ¥430,764,218.24 in the same period of 2021[118]. - The net profit attributable to the parent company was ¥169,486,663.20, a decrease of 3.91% from ¥175,169,586.50 in the previous year[119]. - The total comprehensive income for the period was 891.94 million yuan, a decrease of 9.3% compared to the previous period[130]. - The net profit attributable to shareholders was 227.88 million yuan, representing a decrease of 8.8% compared to the same period last year[130]. Cash Flow and Liquidity - The net cash flow from operating activities turned negative at -¥1,157,613,569.68, a significant decline of 1,552.60% compared to ¥79,692,687.05 in the previous year[20]. - Cash and cash equivalents decreased to ¥1,511,098,250, representing 3.87% of total assets, down from 9.85% last year, a decrease of 5.80%[38]. - The company reported a net cash flow from financing activities of 353,607,134.16 yuan in the first half of 2022, a turnaround from -597,580,668.91 yuan in the same period of 2021[125]. - The total cash inflow from financing activities increased to 2,319,745,425.01 yuan in the first half of 2022, up from 1,856,960,954.54 yuan in the previous year, indicating a growth of approximately 24.8%[125]. - The cash inflow from operating activities totaled 13,756,202,690.70 yuan in the first half of 2022, down from 14,177,461,036.49 yuan in the first half of 2021, indicating a decrease of about 3.0%[124]. Assets and Liabilities - Total assets increased by 2.74% to ¥15,346,471,417.04 from ¥14,937,549,976.72 at the end of the previous year[20]. - Accounts receivable increased to ¥8,221,038,900, accounting for 53.57% of total assets, up from 52.13% last year, an increase of 1.44%[38]. - Inventory rose to ¥2,658,145,320, making up 17.32% of total assets, compared to 14.63% last year, an increase of 2.69%[38]. - Short-term borrowings increased to ¥4,234,737,540, representing 27.59% of total assets, up from 24.88% last year, an increase of 2.71%[39]. - Current liabilities totaled ¥9,335,134,102.02 as of June 30, 2022, compared to ¥9,021,803,540.14 at the start of the year, marking an increase of about 3.49%[111]. Operational Highlights - The pharmaceutical wholesale segment generated ¥11.68 billion, accounting for 91.94% of total revenue, but saw a decline of 3.14% compared to the previous year[34]. - The retail pharmacy segment experienced significant growth, with revenue increasing by 113.75% to ¥875.45 million, representing 6.89% of total revenue[34]. - The company successfully secured distribution qualifications for 67 out of 78 products in the ongoing national bulk procurement program, enhancing its competitive edge[29]. - The company has expanded its e-commerce business model in the health sector, achieving growth despite adverse macroeconomic conditions[28]. - The company is actively developing new medical service businesses, with rehabilitation hospitals in Chengdu, Bengbu, and Shenzhen already completed and operational[28]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company plans to enhance its product structure and regional layout to mitigate the impact of price reductions in pharmaceuticals and medical supplies[54]. - The company is focusing on digital transformation, including the development of smart healthcare and online pharmaceutical distribution[63]. - The company plans to expand its market presence by launching new products in the second half of the year[131]. - The company aims to enhance its operational efficiency by implementing new technologies and optimizing existing processes[135]. Risks and Challenges - The company has acknowledged potential risks related to industry competition, management, market conditions, and national policies[3]. - The company reported a decrease in the weighted average return on equity to 4.12% from 4.71% year-on-year[20]. - The company experienced a credit impairment loss of CNY 2,034,967.95, compared to a gain of CNY 385,909.71 in the same period of 2021[122]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 24,029[95]. - The largest shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of shares, totaling 41,876,430 shares[95]. - The total number of unrestricted sale condition shares is 250,526,315, representing 85.88% of total shares[92]. - The company has not implemented any share buyback or reduction during the reporting period[93]. Compliance and Governance - The semi-annual financial report was not audited[70]. - The financial report complies with the requirements of the enterprise accounting standards, reflecting the financial position and operating results as of June 30, 2022[153]. - The financial statements are prepared based on the going concern principle and historical cost, except for certain financial instruments[150].

Financial Performance - The company's revenue for Q1 2022 was CNY 6,460,665,483.96, representing an increase of 11.19% compared to CNY 5,810,550,826.94 in the same period last year[3] - Net profit attributable to shareholders decreased by 3.65% to CNY 78,838,414.53 from CNY 81,829,097.05 year-on-year[3] - The total revenue for the first quarter was approximately CNY 6.76 billion, a slight decrease from CNY 6.82 billion in the previous year, representing a decline of about 1%[18] - The net profit for the first quarter was CNY 121.40 million, down from CNY 144.89 million year-over-year, indicating a decrease of approximately 16%[17] - Operating profit decreased to ¥167,149,109.01 from ¥199,285,946.50, indicating a decline of 16.1%[16] - The basic earnings per share for the first quarter was CNY 0.27, slightly lower than CNY 0.28 in the previous year[17] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -681,528,106.88, a decline of 415.95% compared to CNY 215,705,560.04 in the previous year[3] - The cash flow from operating activities showed a net outflow of CNY 681.53 million, compared to a net inflow of CNY 215.71 million in the same period last year[20] - Cash and cash equivalents at the end of the period were ¥1,905,282,390.45, down 18.6% from ¥2,338,121,461.75 at the beginning of the year[12] - The company reported a cash and cash equivalents balance of CNY 1.75 billion at the end of the quarter, down from CNY 1.55 billion at the end of the previous year[20] Assets and Liabilities - Total assets increased by 2.68% to CNY 15,337,191,397.86 from CNY 14,937,549,976.72 at the end of the previous year[3] - Total assets reached ¥15,337,191,397.86, up from ¥14,937,549,976.72, reflecting a growth of 2.7%[14] - Total liabilities increased to ¥9,585,873,663.72 from ¥9,280,992,337.21, marking a rise of 3.3%[14] - Shareholders' equity totaled ¥5,751,317,734.14, compared to ¥5,656,557,639.51, showing an increase of 1.7%[14] Operating Costs and Expenses - Total operating costs amounted to ¥6,301,531,573.16, up from ¥5,636,858,890.89, reflecting a year-over-year increase of 11.7%[16] - The company incurred operating expenses of CNY 7.07 billion, up from CNY 6.21 billion year-over-year, reflecting a rise of approximately 14%[18] - The company recorded a 32.5% decrease in minority shareholders' profit to CNY 42,560,380.10 from CNY 63,058,729.85[7] Other Income and Investments - The company reported a 54.8% increase in other income to CNY 13,935,852.35 due to government subsidies received by subsidiaries[6] - Research and development expenses were reported at ¥863,217.54, indicating ongoing investment in innovation[16] - The company raised CNY 1.23 billion through borrowings, significantly higher than CNY 456 million in the same period last year, indicating increased financing activity[20] - The total cash inflow from financing activities was CNY 1.28 billion, compared to CNY 489.51 million in the previous year, showing a substantial increase[20] - The net cash outflow from investing activities was CNY 6.44 million, compared to CNY 4.31 million in the previous year, indicating increased investment expenditures[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,744[9] - The company has no other non-recurring profit and loss items beyond those reported[5]

Financial Performance - The company's revenue for Q1 2022 was CNY 6,460,665,483.96, representing an increase of 11.19% compared to CNY 5,810,550,826.94 in the same period last year[3] - Net profit attributable to shareholders decreased by 3.65% to CNY 78,838,414.53 from CNY 81,829,097.05 year-on-year[3] - The company's net profit for Q1 2022 was RMB 167,149,109.01, a decrease from RMB 199,285,946.50 in the previous year, indicating a decline of 16.14%[16] - The total revenue for the first quarter was approximately CNY 6.76 billion, a slight decrease from CNY 6.82 billion in the previous year, representing a decline of about 0.95%[19] - The net profit for the first quarter was CNY 121.40 million, down from CNY 144.89 million year-over-year, indicating a decrease of approximately 16.16%[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -681,528,106.88, a decline of 415.95% compared to CNY 215,705,560.04 in the previous year[3] - The cash flow from operating activities showed a net outflow of CNY 681.53 million, compared to a net inflow of CNY 215.71 million in the same period last year[19] - Cash and cash equivalents at the end of Q1 2022 were RMB 1,905,282,390.45, down from RMB 2,338,121,461.75 at the beginning of the year, representing a decrease of 18.56%[12] - The company reported a cash and cash equivalents balance of CNY 1.75 billion at the end of the quarter, down from CNY 1.55 billion at the end of the previous year[21] - The company raised CNY 1.23 billion through borrowings, significantly higher than CNY 456 million in the same period last year, indicating a strong financing activity[21] - The total cash inflow from financing activities was CNY 1.28 billion, compared to CNY 489.51 million in the previous year, showing a substantial increase[21] - The company incurred a cash outflow of CNY 970.07 million for debt repayment, which is slightly higher than CNY 929.91 million in the previous year[21] - The net cash flow from investing activities was negative at CNY 6.44 million, worsening from a negative CNY 4.31 million in the previous year[21] Assets and Liabilities - Total assets increased by 2.68% to CNY 15,337,191,397.86 from CNY 14,937,549,976.72 at the end of the previous year[3] - Total liabilities increased to RMB 9,585,873,663.72 from RMB 9,280,992,337.21, indicating a rise of 3.28%[14] - The company's equity attributable to shareholders reached RMB 3,966,293,521.25, up from RMB 3,886,549,170.39, reflecting an increase of 2.05%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,744[9] - The top shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of the shares, totaling 41,876,431 shares[9] Operational Insights - Total operating costs for Q1 2022 were RMB 6,301,531,573.16, up from RMB 5,636,858,890.89, reflecting a year-over-year increase of 11.74%[16] - The company did not report any new product developments or market expansion strategies in this quarter[3] - Research and development expenses for Q1 2022 were RMB 863,217.54, indicating ongoing investment in innovation[16] - The company reported a significant decrease in the disposal of assets, with asset disposal income dropping by 92.1% to CNY 27,897.69[6] - The company did not report any net profit from subsidiaries under common control during the quarter, consistent with the previous year[18] Inventory and Receivables - Accounts receivable increased to RMB 8,128,526,887.18 from RMB 7,787,339,611.18, marking a rise of 4.39%[12] - Inventory at the end of Q1 2022 was RMB 2,425,479,882.35, up from RMB 2,185,383,123.69, reflecting an increase of 11.01%[12]

嘉事堂药业股份有限公司 2022 年第一季度报告全文 证券代码：002462 证券简称：嘉事堂 公告编号：2022-14 嘉事堂药业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 6,460,665,483.96 | 5,810,550,826.94 | 11.19% | | 归属于上市公司股东的净利润（元） | 78,838,414.53 | 81,829,097.05 ...

Financial Performance - The company's operating revenue for 2021 was CNY 25,625,618,769.65, representing a 10.19% increase compared to CNY 23,256,135,891.33 in 2020[18]. - The net profit attributable to shareholders for 2021 was CNY 353,876,773.64, an increase of 11.43% from CNY 317,585,422.67 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 346,379,731.51, up 10.92% from CNY 312,280,514.92 in 2020[18]. - The basic earnings per share for 2021 was CNY 1.21, reflecting an increase of 11.01% compared to CNY 1.09 in 2020[18]. - The total assets at the end of 2021 amounted to CNY 14,937,549,976.72, a 5.69% increase from CNY 14,133,717,238.25 at the end of 2020[18]. - The net assets attributable to shareholders at the end of 2021 were CNY 3,886,549,170.39, which is a 7.10% increase from CNY 3,628,935,746.35 in 2020[18]. - The net cash flow from operating activities for 2021 was CNY 913,127,423.08, a decrease of 18.10% from CNY 1,114,869,517.58 in the previous year[18]. - The company reported a loss of CNY 7.01 million from other non-operating income and expenses, an improvement from a loss of CNY 10.50 million in 2020[24]. - The total revenue for Jia Shi Tang Pharmaceutical Co., Ltd. in 2021 was CNY 25,625,618,769.65, representing a year-on-year increase of 10.19% compared to CNY 23,256,135,891.33 in 2020[44]. - The net profit for 2021 was CNY 601.88 million, an increase of 1.86% compared to the previous year[41]. Revenue Segmentation - The pharmaceutical wholesale segment generated CNY 23,991,152,990.55, accounting for 93.62% of total revenue, but saw a decline of 3.72% from the previous year[44]. - The pharmaceutical retail segment experienced significant growth, with revenue increasing by 235.26% to CNY 1,270,721,190.54, driven by rapid expansion in e-commerce[47]. - The pharmaceutical logistics segment saw a revenue increase of 51.85% to CNY 363,744,588.56, reflecting growth in this area[47]. Strategic Initiatives - The company focused on enhancing logistics management and third-party business cooperation, which contributed to operational efficiency[31]. - The company continued to optimize its product resources and structure in response to national procurement policies, supporting sales growth[32]. - The company emphasized risk control and management, implementing stricter auditing and receivables management practices[33]. - The company plans to respond to policy changes in drug procurement and enhance business research and management coordination in 2022[74]. - The company aims to strengthen its operational system and establish core operational indicators for sustainable growth in 2022[75]. - The company is actively exploring online business models and implementing key projects to drive new business growth[77]. - The company has established a leadership group for targeted poverty alleviation and rural revitalization projects[148]. Governance and Management - The company maintained independent operations from its controlling shareholder, ensuring no interference in decision-making processes[92]. - The company established effective performance evaluation and incentive mechanisms, continuously improving them[88]. - The company ensured transparent information disclosure, complying with relevant laws and regulations to provide accurate and timely information to shareholders[90]. - The company has a well-structured organization with a complete procurement, sales, and logistics distribution system[94]. - The company has appointed independent directors to enhance governance and oversight[98]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 10.86 million[117]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for 2022, driven by new product launches and market expansion strategies[99]. - The company is investing in R&D for new technologies, with an allocated budget of 50 million for the development of innovative pharmaceutical products[99]. - Market expansion efforts include entering three new regional markets, aiming for a 10% market share in each by the end of 2022[99]. - A new product line is set to launch in Q3 2022, expected to contribute an additional 30 million in revenue[99]. - The management team has undergone changes, with the appointment of new executives to strengthen leadership and operational efficiency[100]. Social Responsibility and Community Engagement - The company actively participates in rural revitalization efforts, aligning with national policies and providing quality medical services[145]. - The company has allocated 500,000 RMB for targeted assistance funds to support designated poverty alleviation counties in Hunan[151]. - The company has implemented a "green office" initiative to promote energy conservation and resource recycling[143]. - The company emphasizes social responsibility through practical actions in community support and public welfare[145]. Shareholder Information - The total number of shares is 291,707,100, with 14.59% being restricted shares and 85.41% being unrestricted shares[185]. - The largest shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of the shares, totaling 41,876,430 shares[187]. - The company has 23,685 total shareholders at the end of the reporting period[187]. - The company did not issue any new shares or conduct any stock splits during the reporting period[186]. - The controlling shareholder has committed to not transferring shares acquired through this transaction for 36 months following the issuance[192].

Financial Performance - The company's revenue for Q3 2021 was ¥6,789,118,230.69, representing a year-on-year increase of 3.23%[3] - The net profit attributable to shareholders for Q3 2021 was ¥90,449,294.09, a decrease of 17.25% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥88,418,320.32, down 17.96% year-on-year[3] - The basic earnings per share for Q3 2021 was ¥0.30, a decrease of 18.08% compared to the same period last year[3] - Total operating revenue for the current period reached ¥19,350,905,221.84, an increase of 18.9% compared to ¥16,288,560,957.27 in the previous period[18] - Total operating costs amounted to ¥18,733,139,755.97, up 19.5% from ¥15,681,790,040.81 in the prior period[18] - Operating profit for the current period was ¥646,384,309.00, representing a 12.1% increase from ¥576,046,684.31 in the previous period[19] - Net profit for the current period was ¥466,993,621.42, an increase of 7.8% compared to ¥433,168,445.94 in the same period last year[19] - The company reported a basic earnings per share of ¥0.91, up from ¥0.84 in the previous period[20] - Other income increased to ¥25,286,954.89 from ¥16,174,470.91 in the previous period, reflecting a growth of 56.5%[19] Cash Flow - The operating cash flow for the year-to-date period was ¥178,741,693.17, reflecting a significant decline of 46.68%[3] - Cash flow from operating activities totaled ¥21,361,860,431.16, compared to ¥17,877,382,937.26 in the previous period[21] - Cash flow from investing activities resulted in a net outflow of ¥38,320,605.14, improving from a net outflow of ¥58,224,041.63 in the prior period[23] - Cash flow from financing activities showed a net outflow of ¥440,398,843.78, slightly worse than the net outflow of ¥421,018,996.99 in the previous period[24] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥14,367,033,204.67, an increase of 1.65% from the end of the previous year[3] - Current assets totaled CNY 12,815,086,837.49, compared to CNY 12,567,156,348.84 at the end of 2020, reflecting a growth of approximately 1.97%[14] - Total liabilities stood at CNY 8,821,235,830.29, slightly up from CNY 8,809,686,211.29, indicating a marginal increase[15] - The company's equity attributable to shareholders increased by 4.67% to ¥3,798,291,277.34 compared to the end of the previous year[4] - The company's equity attributable to shareholders reached CNY 3,798,291,277.34, up from CNY 3,628,935,746.35, marking an increase of about 4.67%[16] - The company reported a decrease in short-term borrowings to CNY 3,470,540,955.19 from CNY 3,558,263,244.51, a reduction of approximately 2.5%[15] Inventory and Receivables - Accounts receivable increased to CNY 8,010,878,527.55 from CNY 7,648,002,240.45, representing a growth of approximately 4.75%[14] - Inventory increased to CNY 2,107,667,945.24 from CNY 2,013,591,273.23, reflecting a growth of about 4.67%[14] Government Subsidies and Other Income - The company received government subsidies totaling ¥5,779,473.04 during the reporting period, which is part of the non-recurring gains[6] - The company reported a 56.34% increase in other income due to higher government tax refunds received[8] Compliance and Reporting - The third quarter report of Jia Shitang Pharmaceutical Co., Ltd. is unaudited[25] - The company implemented new leasing standards starting from 2021, with no adjustments made to prior comparative data[25] - The board of directors announced the financial report on October 23, 2021[25] - There are no adjustments to the financial statements related to the new leasing standards for the first year of implementation[25] - The company did not apply retrospective adjustments for prior comparative data under the new leasing standards[25] - The financial report does not include any significant user data or performance guidance[25] - There are no mentions of new product development or market expansion strategies in the report[25] - The report does not indicate any mergers or acquisitions planned by the company[25] - The company has not disclosed any new strategies in the financial report[25] - The report is focused solely on compliance with new accounting standards without detailed financial performance metrics[25]

1 证券简称：嘉事堂 证券代码： 002462 公告编号：2021-047 嘉事堂药业股份有限公司 关于参加北京辖区 上市公司投资者集体接待日的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 为进一步加强与广大投资者的沟通交流，嘉事堂药业股份有 限公司（以下简称"公司"）将参加"2021 年北京辖区上市公司 投资者集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将采取网络远程的方式举行，投资者可 以登录"全景网"网站（http://rs.p5w.net）参与本次投资者集 体接待日活动，活动时间为 2021 年 9 月 23 日（星期四）15:00 至 17:00。 届时公司的董事长续文利先生、总裁黄奕斌先生、董事会秘 书王新侠女士将通过网络在线交流形式与投资者就公司治理、发 展战略、经营状况、融资计划、股权激励和可持续发展等投资者 关注的问题进行沟通。 欢迎广大投资者积极参与。 嘉事堂药业股份有限公司 2021 年 9 月 9 日 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥12,561,786,991.15, representing a 29.35% increase compared to ¥9,711,728,693.95 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥175,169,586.50, up 29.12% from ¥135,661,448.28 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥170,034,213.83, reflecting a 30.00% increase from ¥130,794,996.51 in the same period last year[20]. - The basic earnings per share increased by 27.66% to ¥0.60 from ¥0.47 in the previous year[20]. - The company achieved a revenue of 12.562 billion yuan in the first half of 2021, representing a year-on-year growth of 29.35%[29]. - The net profit attributable to the listed company was 175 million yuan, an increase of 29.12% compared to the previous year[29]. - The total profit for the first half of 2021 was CNY 430,764,218.24, compared to CNY 314,449,772.89 in the same period last year, marking a rise of 37.0%[120]. - The company's operating profit reached CNY 435,333,242.72, an increase of 39.5% from CNY 312,082,838.90 in the previous year[120]. - The total comprehensive income for the first half of 2021 was CNY 311,244,856.45, compared to CNY 235,278,418.18 in the same period of 2020, reflecting a growth of 32.3%[120]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 71.15% to ¥79,692,687.05 from ¥276,189,753.86 in the same period last year[20]. - The net cash flow from investing activities worsened by 61.60% to -¥8,058,483.83, due to new business expansion and fixed asset investments[37]. - The net cash flow from financing activities increased by 109.40% to -¥597,580,668.91, resulting from reduced bank borrowings and increased dividends from subsidiaries[37]. - The net increase in cash and cash equivalents was -¥525,946,465.69, a significant decline of 3,615.70% compared to -¥14,154,860.74 in the previous year, mainly due to reduced bank borrowings[37]. - Cash and cash equivalents decreased to CNY 1,503,120,716.78 from CNY 2,018,504,935.00 at the end of 2020, representing a decline of approximately 25.4%[109]. - The ending balance of cash and cash equivalents was ¥1,352,822,100.11, a decrease from ¥1,417,209,067.94 at the end of the previous year[128]. Assets and Liabilities - Total assets at the end of the reporting period were ¥14,146,071,146.95, a slight increase of 0.09% from ¥14,133,717,238.25 at the end of the previous year[20]. - The total liabilities of the company were not explicitly stated but can be inferred from the balance sheet data provided[110]. - The company's total equity increased to ¥5,371,576,609.41 from ¥5,324,031,026.96, indicating a positive trend in shareholder value[112]. - The company's total assets at the end of the reporting period were approximately 3,034.86 million yuan, indicating growth in asset value[144]. Operational Strategies - The company focused on enhancing its drug sales in key hospitals, resulting in a significant increase in collaboration with upstream and downstream clients[28]. - The high-value consumables sales business continued to grow steadily, supported by the company's brand advantages and professional resources[28]. - The company optimized logistics resources and strengthened cooperation with well-known foreign pharmaceutical companies, improving service efficiency[28]. - The company actively implemented a merger and acquisition strategy to capitalize on industry consolidation opportunities, enhancing its national business layout[31]. - The company emphasized risk management and internal control systems to ensure the safety of state-owned assets and improve operational efficiency[32]. - The company is committed to exploring new business models, including medical device supply chain services and in-hospital information services, to create new profit growth points[33]. Shareholder Information - The company reported a total of 291,707,100 shares outstanding, with 85.60% being unrestricted shares[93]. - The largest shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of the shares, totaling 41,876,431 shares[95]. - The company did not distribute cash dividends or issue new shares from capital reserves during the reporting period[61]. Research and Development - The company reported a significant increase in research and development expenses, although specific figures are not provided, indicating a commitment to innovation[117]. - The company plans to continue its focus on research and development for new products and technologies to enhance market competitiveness[141]. Financial Reporting and Compliance - The half-year financial report has not been audited, indicating a need for further financial scrutiny[71]. - The financial statements are prepared based on the "Enterprise Accounting Standards" and reflect the company's financial position as of June 30, 2021, and its operating results for the first half of 2021[154]. - The company follows a calendar year for its accounting period, from January 1 to December 31[155].

Financial Performance - The company's revenue for Q1 2021 reached ¥5,810,550,826.94, representing a 43.51% increase compared to ¥4,048,898,332.23 in the same period last year[7] - Net profit attributable to shareholders was ¥81,829,097.05, up 60.51% from ¥50,980,357.36 year-on-year[7] - Basic and diluted earnings per share increased to ¥0.28, a rise of 64.71% from ¥0.17 in the same quarter last year[7] - Total operating revenue for the quarter reached ¥5,810,550,826.94, an increase of 43.51% compared to ¥4,048,898,332.23 in the previous period[14] - Net profit attributable to shareholders of the parent company was ¥81,829,097.05, up 60.51% from ¥50,980,357.36 in the same period last year[16] - The company reported a net profit increase in retained earnings to CNY 1,940,217,947.77 from CNY 1,858,388,850.74, reflecting an increase of approximately 4.39%[33] - The total profit for Q1 2021 was ¥202,056,848.63, up 83.5% from ¥110,159,970.12 in the previous year[40] Cash Flow - The net cash flow from operating activities improved significantly to ¥215,705,560.04, compared to a negative cash flow of ¥199,951,828.35 in the previous year, marking a 207.88% change[7] - The company achieved a net cash flow from operating activities of ¥215,705,560.04, a significant improvement from a negative cash flow of -¥199,951,828.35 in the previous period[16] - Cash inflow from operating activities totaled CNY 6,901,727,979.73, up from CNY 5,112,966,561.27, indicating a growth of 35.05%[48] - Cash outflow for purchasing goods and services was CNY 6,213,614,549.07, compared to CNY 4,958,946,989.21 in the previous period, an increase of 25.31%[48] - The company’s cash flow from operating activities was negatively impacted by increased payments to suppliers and employees, totaling CNY 6,686,022,419.69 in cash outflows[48] Assets and Liabilities - The total assets at the end of the reporting period were ¥14,051,071,264.83, a slight decrease of 0.58% from ¥14,133,717,238.25 at the end of the previous year[7] - The company’s total liabilities increased by 36.02% in other payables, amounting to ¥491,991,021.46, due to temporary advances to minority shareholders[14] - Total liabilities decreased to CNY 8,618,231,704.02 from CNY 8,809,686,211.29, reflecting a decline of approximately 2.17%[32] - The company's equity attributable to shareholders increased to CNY 3,710,764,843.40 from CNY 3,628,935,746.35, marking an increase of about 2.25%[33] - Current assets totaled CNY 12,510,203,493.83, slightly down from CNY 12,567,156,348.84, indicating a decrease of about 0.45%[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,316[10] - The top shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of the shares, totaling 41,876,431 shares[10] Operating Costs and Expenses - The total cost of operating reached ¥5,636,858,890.89, reflecting a 43.20% increase due to the corresponding rise in revenue[14] - The company’s sales expenses increased to ¥215,255,266.55, a rise of 40.5% compared to ¥153,147,544.00 in Q1 2020[39] - The company’s income tax expense increased by 101.02% to ¥57,169,021.73, reflecting the growth in profit[15] Investment and Development - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[39] - The company reported a significant increase in investment income, rising to ¥8,067,486.63 from ¥4,317,890.85 year-on-year[43] Other Financial Metrics - The weighted average return on equity was 2.23%, an increase of 0.75% compared to 1.48% in the previous year[7] - The company’s gross profit margin improved, with operating profit rising to ¥199,285,946.50, a 75.69% increase from ¥113,429,911.76 in the previous period[15] - Total comprehensive income for the first quarter was CNY 37,587,394.06, compared to CNY 25,664,651.35 in the previous period, representing a significant increase[45] - Basic and diluted earnings per share increased to CNY 0.13 from CNY 0.09, reflecting a growth of 44.44%[45]

Financial Performance - The company's operating revenue for 2020 was CNY 23,256,135,891.33, representing a 4.82% increase compared to CNY 22,186,572,874.61 in 2019[16] - The net profit attributable to shareholders for 2020 was CNY 317,585,422.67, a decrease of 15.53% from CNY 375,957,176.99 in 2019[16] - The net cash flow from operating activities increased significantly by 280.35% to CNY 1,114,869,517.58, compared to CNY 293,114,556.75 in 2019[16] - The total assets at the end of 2020 were CNY 14,133,717,238.25, an increase of 8.41% from CNY 13,037,391,923.99 at the end of 2019[17] - The net assets attributable to shareholders increased by 5.94% to CNY 3,628,935,746.35 from CNY 3,425,524,154.59 in 2019[17] - The basic earnings per share for 2020 was CNY 1.09, down 24.31% from CNY 1.44 in 2019[16] - The company reported a weighted average return on equity of 9.01%, down from 13.38% in 2019[16] - The quarterly operating revenue for Q4 2020 was CNY 6,967,574,934.06, showing a strong performance in the last quarter[20] Revenue Breakdown - Pharmaceutical wholesale revenue accounted for ¥22.64 billion, which is 97.34% of total revenue, showing a slight decrease of 0.72% compared to ¥21.76 billion in 2019[36] - Revenue from the Beijing region decreased by 4.84% to ¥8.55 billion, while revenue from other regions increased by 4.84% to ¥14.70 billion[36] - The gross profit margin for pharmaceutical wholesale was 8.77%, a decrease of 1.37% from the previous year[39] - Sales volume for pharmaceutical wholesale increased by 4.05% to ¥22.64 billion, while inventory decreased by 12.37% to ¥1.94 billion[41] Cash Flow and Investments - The company reported a 28% increase in cash and cash equivalents, attributed to timely collection of receivables[29] - The total cash inflow from operating activities was ¥25,427,615,623.77 in 2020, up 3.40% from ¥24,592,375,383.27 in 2019[48] - The net cash flow from financing activities decreased by 172.38% to -¥373,545,649.76 in 2020 from ¥516,115,013.34 in 2019[49] - The company's cash flow from investment activities saw a net outflow of -¥293,544,718.21 in 2020, a decrease of 7.89% from -¥318,698,984.95 in 2019[48] Dividend Distribution - The company plans to distribute a cash dividend of CNY 3.3 per 10 shares, totaling CNY 96,000,000 based on 291,707,120 shares[4] - The cash dividend for 2020 represented 30.31% of the net profit attributable to ordinary shareholders, while the 2019 and 2018 dividends were 31.04% and 11.47%, respectively[87] - The total cash dividend for 2020, including other methods, was 96,263,349.60 CNY, which accounted for 8.26% of the total profit distribution[88] Research and Development - R&D personnel increased to 146 in 2020 from 12 in 2019, a growth of 1,116.67%[47] - R&D investment rose to ¥23,565,800 in 2020 from ¥1,500,000 in 2019, an increase of 1,471.05%[47] - The proportion of R&D investment to operating revenue was 0.10% in 2020, up from 0.01% in 2019[47] Corporate Governance - The company maintains a strict governance structure in compliance with relevant laws and regulations, ensuring independent operations from its controlling shareholder[177] - The company has established a complete independent business system, with no reliance on related transactions for its main business income and profits[180] - All senior management personnel are appointed through legal procedures, ensuring independence from the controlling shareholder[181] Social Responsibility - The company reported a total of 370 million RMB invested in targeted poverty alleviation efforts in Hunan province[128] - Direct donations of 2.3 million RMB were made through the Everbright Trust account for poverty alleviation initiatives[128] - During the pandemic, the company donated nearly 200,000 RMB worth of anti-epidemic supplies to designated poverty alleviation counties[128] Subsidiaries and Market Position - The company established several new subsidiaries in 2020, including Shanghai Jiashiluexi Medical Equipment Co., Ltd. and Jiangsu Jiashijimei Medical Technology Co., Ltd.[42] - The company maintained its leading position in pharmaceutical distribution in Beijing while expanding its medical device and consumables services nationwide[26] Audit and Compliance - The audit report issued by Ernst & Young Huaming Certified Public Accountants provided a standard unqualified opinion on the financial statements for the year ended December 31, 2020[199] - There were no significant deficiencies identified in the internal control evaluation report for the reporting period[191] Employee Information - The total number of employees in the company is 3,031, with 2,780 in major subsidiaries and 251 in the parent company[170] - The total remuneration for directors and senior management during the reporting period amounts to 979.41 million yuan[170] - The company has 2,225 sales personnel, making up the largest segment of its workforce[170]